Simulations Plus's Days Sales Outstanding for the
three
months ended in Feb. 2026 was 57.47.
Simulations Plus's Days Inventory for the
three
months ended in Feb. 2026 was 0.
Simulations Plus's Days Payable for the
three
months ended in Feb. 2026 was 9.43.
Therefore, Simulations Plus's Cash Conversion Cycle (CCC) for the
three
months ended in Feb. 2026 was 48.04.
Simulations Plus (FRA:SD3) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Simulations Plus Cash Conversion Cycle Related Terms
Simulations Plus Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Simulations Plus's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SD3 vs TBRG, CARL, NRC: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, Simulations Plus's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Simulations Plus's Cash Conversion Cycle falls into.
Simulations Plus Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Simulations Plus's Cash Conversion Cycle for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (FRA:SD3) has a Cash Conversion Cycle of 48.04 as of Feb. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Simulations Plus and its competitors.
Is Simulations Plus' Cash Conversion Cycle too high?
Simulations Plus' current Cash Conversion Cycle is 48.04. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.91. Simulations Plus' value of 48.04 is 168.2% above this industry median. Overall, Simulations Plus has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' Cash Conversion Cycle compare to TBRG and CARL?
Simulations Plus' Cash Conversion Cycle of 48.04 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.91. Simulations Plus' value of 48.04 is 168.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.91, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current Cash Conversion Cycle of 48.04 is 168.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current Cash Conversion Cycle is 48.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (FRA:SD3) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.93, compared to a current price of €15.80 — trading 52% below its estimated fair value. The current Cash Conversion Cycle is 48.04 and 168.2% above the Healthcare Providers & Services industry median of 17.91. Simulations Plus' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Simulations Plus (FRA:SD3), the current Cash Conversion Cycle is 48.04 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (FRA:SD3) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of €15.80 is trading 52% below its estimated GF Value™ of €32.93.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for FRA:SD3:
Cash Conversion Cycle: 48.04
GF Value™: €32.93 vs. price of €15.80 (52% below fair value)
Industry Position: 168.2% above the Healthcare Providers & Services median
No single metric tells the full story. See the FRA:SD3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
67GF Score
Get the complete analysis for FRA:SD3
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SD3 has been successfully added to your 
